In vivo efficacy of oral and intraperitoneal administration of extracts of Warburgia ugandensis (Canellaceae) in experimental treatment of old world cutaneous leishmaniasis caused by Leishmania major. by Ngure, P et al.
Ngure et al., Afr. J. Trad. CAM (2009) 6 (2): 207 - 212 
 
207 




IN VIVO EFFICACY OF ORAL AND INTRAPERITONEAL ADMINISTRATION OF 
EXTRACTS OF WARBURGIA UGANDENSIS (CANELLACEAE) IN EXPERIMENTAL 
TREATMENT OF OLD WORLD CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA 
MAJOR. 
 
1*Peter Kamau Ngure, 3Zipporah Ng’ang’a, 2Johnstone Ingonga 2Geoffrey Rukunga 
and 2Willy Kiprotich Tonui. 
 
1Daystar University, Science department, P.O. Box 44400, 00100, Nairobi. 2Kenya Medical 
Research Institute. 3Jomo Kenyatta University of Agriculture and Technology. 





The antileishmanial activity of extracts of Warburgia ugandensis Spraque (Canellaceae), a 
known traditional therapy in Kenya was evaluated in vivo. Treatment of infected BALB/c mice with W. 
ugandensis extracts orally resulted in a reduction of the size of lesions compared to the untreated 
control. The lesion sizes differed significantly for the four extracts (p=0.039) compared to the untreated 
control. For mice treated by intraperitoneal injection, the lesion sizes increased initially for the hexane, 
dichloromethane and ethyl acetate extracts and healed by day 42. The lesion sizes for mice treated 
with methanol increased steadily from 2.47mm to 3.57mm. The parasitic burden was significantly 
higher (p<0.001) in mice treated with methanol extracts and PBS compared to those treated with 
hexane, dichloromethane and ethyl acetate. This study demonstrated the antileishmanial potential of 
extracts of W. ugandensis.  
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The leishmaniases are diseases caused by obligate intracellular, kinetoplastid protozoa of the 
genus Leishmania (Trypanosomatidae) (Roberts, 2006). Although it is not a household name like 
malaria, the diseases caused by infection with Leishmania continue to have a major impact on much 
of the world’s population and are currently considered to be an emerging illness with high morbidity 
and mortality in the tropics and subtropics (Handman, 2001; Santos et al., 2008).  Neglected by 
researchers and funding agencies, leishmaniases are endemic in 88 countries of the World in which 
350 million people who are considered at risk of infection live (WHO, 2007). There are 2 million new 
cases of leishmaniasis annually and 14 million infected people worldwide (WHO, 2007).  
An increase in the incidence of leishmaniasis can be associated with urban development, 
destruction of forests, environmental changes, migrations of people to areas where the disease is 
endemic and wars which contributes to the spread due to displacement of people (Ashford, 2000; Patz 
et al., 2000; Kolaczinski et al., 2007).  
Proven therapies against human leishmaniasis include pentavalent antimonials (sodium 
stibogluconate and meglumine antimoniate), amphotericin B, pentamidine, miltefosine and 
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paromomycin (Berman, 1996, 1997). These drugs are unsatisfactory because of their limited efficacy, 
frequent side effects, and increasing drug resistance, therefore new, safer, and more efficacious drugs 
are urgently required (Croft and Seifert, 2005). Moreover, there is no effective vaccine against 
leishmaniasis (Handman, 2001). In this regard, medicinal plants offer prospects for discovering new 
compounds with therapeutic properties. 
Warburgia ugandensis Sprague (Canellaceae), the East African greenheart  is one of the most 
highly utilized medicinal plants in tropical and subtropical Africa and is now highly endangered in the 
wild (Kioko et al., 2005). It is rated as the second highest priority medicinal plant species in Kenya 
(Kariuki and Simiyu, 2005).  According to the World Agroforestry Centre, (http://www 
Worldagroforetsrycentre.org/sea/products/AFDbases/af/asp/SpeciesInfo) the dried bark of the tree is 
commonly chewed and the juice swallowed as a remedy for stomach ache, constipation, toothache, 
venereal diseases, cough, fever, muscle pains, weak joints and general body pains.  The leaf 
decoction baths are used as a cure for skin diseases while the bark, roots, or leaves can be boiled in 
water and drunk to treat malaria, although this causes violent vomiting.  
Warburgia ugandensis which is known as “soket” in Tugen tribe is used by traditional healers 
to treat visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) (W. Tonui, Kenya Medical 
Research Institute, Nairobi, personal Communication). The stem barks are taken orally in boiled water 
or soup.  
Previous studies on W. ugandensis have shown good antibacterial, antifungal, antiviral activity 
and trypanocidal effects. Crude extracts and purified compounds of W. ugandensis showed activity 
against Mycobacterium tuberculosis H37Rv and M. Bovis BCG Pasteur (Madikane et al., 2007), 
Candida albicans and measles virus (Olila et al., 2001, 2002). Similarly, the activity of W. ugandensis 
against trypanosomes has been demonstrated (Kioy et al., 1998; Olila et al., 2001). A recent study 
demonstrated that hexane, dichloromethane and ethyl acetate extracts of W. ugandensis had good 
antileishmanial activity in vitro (Ngure et al., 2008, unpublished report).  
The objective of the present study was to determine the effect of extracts of W. ugandensis on 
Leishmania major infected BALB/c mice. 
 
 
Materials and Methods 
Source of W. ugandensis 
 
Warburgia ugandensis stem barks (CTMDR 007) were collected from Sesia village in 
Kabarnet, Baringo District, in the Rift Valley Province in Kenya. Botanical identification was done using 
standard identification keys by the National Museums of Kenya botanists.  Voucher specimens were 
kept in the Kenya Medical Research Institute laboratory in Nairobi. 
 
Sample preparation and extraction of compounds of W. ugandensis 
 
The stem barks were cut into small pieces and air-dried for three weeks under a shed.  The 
dried specimens were shred using an electrical mill in readiness for extraction.  The sample 
preparation and extraction procedure were carried out as described by Harbone (1994).  Cold 
sequential extraction was carried out on plant material with analar grade organic solvents of increasing 
polarity, which included n-hexane, dichloromethane, ethyl acetate and methanol.  Six hundred 
millilitres of n-hexane was added to 300gms of the shred specimen and flasks placed on a shaker and 
soaked for 48 hrs. The residue was filtered using a Buchner funnel under vacuum until the sample 
dried.  The sample was soaked further with 600ml of n-hexane for 24 hrs until the filtrate remained 
clear.  The filtrate was then concentrated under vacuum by rotary evaporation at 30-350C (Harborne, 
1994).  The concentrate was transferred to a sample bottle and dried under vacuum; the weight of the 
dry extract was recorded and stored at -200C until required for bioassay.  The process was repeated 
sequentially for dichloromethane, ethyl acetate and methanol. 
 
 
Testing for antileishmanial activity of extracts of  W. ugandensis 
Experimental animals 
 
Eight week old BALB/c mice were obtained from the Kenya Medical Research Institute’s (KEMRI) 
animal house facility. The experiments using mice were done in compliance with the Animal Care and 
Use Committee (ACUC) guidelines of KEMRI. 
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Leishmania parasites  
 
Metacyclic promastigotes of L. major strain (Strain IDU/KE/83 =NLB-144) were used. 
Parasites were maintained as previously described (Titus et al., 1984) and metacyclics were isolated 
from stationary phase cultures by negative selection using peanut agglutinin (Tonui et al., 2004).  
Briefly, the promastigotes were cultured in Schneider’s Drosophila medium supplemented with 20% 
foetal bovine serum (FBS), glutamine (2mM), penicillin G (100 U/ml), and streptomycin (100 µg/ml). 
Stationary-phase promastigotes were obtained from 5 to 7-day-old cultures.  
 
Preparation of drugs 
 
Stock solutions of the fractions were made in culture media for anti-leishmanial assay and re-
sterilized by passing through 0.22 µm micro-filters under sterile conditions in a laminar flow hood.  The 
extracts that were insoluble in water or media were first dissolved in 1% dimethyl sulphoxide to avoid 
solvent carry over, (Dorin et al., 2001).  All the prepared drugs were stored at 40C and retrieved only 
during use. 
 
Infection of mice, treatment and determination of p arasite numbers in cutaneous lesions 
 
Female BALB/c mice were infected in the hind footpad with 1 x106 L. major metacyclic 
promastigotes. In all experiments, treatment was initiated 4 or 5 weeks after infection had established 
as determined by the presence of lesions (Fournet et al., 1996). Two days before administration of the 
drug, the mice were randomly divided into groups of ten.  Infected untreated mice were used as 
controls. Experimental mice were treated with the standard drug pentostam, in regimens of 20mg of 
Sb per body weight daily for 30 days intraperitoneally while others were treated with amphotericin B.  
The extracts were injected intraperitoneally or administered orally using a cannula daily for 30 
days. The untreated group received PBS.  Lesion development was followed by measuring thickness 
of the infected footpad as compared to the thickness of the contralateral footpad prior to infection 
using a vernier caliper. All mice were sacrificed during the 12th week, spleens were weighed and 
impression smears made. These were fixed in absolute methanol and stained with Giemsa before 




All experiments were carried out in triplicate. The mean and standard deviation of at least 
three experiments was determined. Statistical analysis of the differences between mean values 
obtained for the experimental groups was done by analysis of variance (ANOVA) and Student’s t test. 
P values of 0.05 or less were considered significant.  
 
Results and discussion 
 
Three hundred grams of the stem barks of W. ugandensis yielded 10.5 g for n-hexane extract, 
12.1g for dichloromethane, 9.3g for ethyl acetate and 9.9g for the methanol extract.   
This study examined the antileishmanial activity of extracts of W.  ugandensis in vivo. The 
administration of hexane, dichloromethane, and ethyl acetate extracts led to the recovery of BALB/c 
mice infected with L. major. The results are in agreement with the claims made by Kenyan traditional 
practitioners that W. ugandensis stem barks have antileishmanial effects (W. Tonui, 2006, 
unpublished report).   
             There was no significant difference (p=0.697) in body weight change for mice that were 
treated orally using a cannula compared to those that were treated by intraperitoneal injection. There 
was also no significant difference (p=0.462) in change of body weight for mice that were treated  with 
pentostam and amphotericin B compared with those that were treated orally with the hexane, 
dichloromethane, ethyl acetate and methanol extracts. Similarly, there was no significant difference 
(p=0.260) between mice treated with pentostam and amphotericin B and those treated 
intraperitoneally with the four extracts. The administration of the extracts did not have any adverse 
effects on mice considering that there were no observable changes in mice. Since so far there is no 
documented report on in vivo studies using W. ugandensis extracts it was necessary to ascertain that 
the test samples did not affect laboratory mice. 
Footpad swelling developed in mice within two weeks post infection. Treatment of infected 
BALB/c mice with W. ugandensis extracts resulted in reduced swellings compared to the negative 
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control. The changes in lesion sizes after treatment with extracts of W. ugandensis orally are as 
shown in Table 1.  The lesion sizes increased initially for the extracts reaching a peak by day 28 post 
infection then reduced in size by day 42.  The difference in lesion sizes was not significant in the 
different days (p=0.590) but differed significantly for the four extracts (p=0.039) and the negative 
control.  Treatment with the four extracts stopped the development of lesions after 40 days. On the 
other hand, lesions for mice treated with PBS increased steadily from 2.27 mm reaching a peak of 4.0 
mm by the end of the12th week. 
 
Table 1:  Mean lesion size for L. major infected BALB/c mice after treatment with extracts of W. 
ugandensis orally. The data is presented as mean ± Standard deviation of experiments done 
in triplicates. 
 
Mean lesion size ±SD 
 ____________________________________________________________ 
Treatment    Day 14   Day 28           Day 42 
_________________________________________________________________________________
   
Hexane               0.133±0.09               0.177±0.09      0.267±0.22       
Dichloromethane             0.433±0.43            0.333±0.20     0.233±0.23        
Ethyl acetate            0.867±0.20               0.467±0.15    0.400±0.20  
PBS             0.800±0.25         0.967±0.03  1.733±0.03 
________________________________________________________________________________ 
 
Table 2: . Mean lesion sizes for L. major infected BALB/c mice after treatment with extracts of W. 
ugandensis by intraperitoneal injection. The data is presented as mean ± Standard deviation 
of experiments done in triplicates.  
 
                               Mean lesion size ±SD
 ___________________________________________________________________________ 
Treatment   Day 14   Day 28  Day 42 
_________________________________________________________________________________  
Hexane               0.467±0.27      0.233±0.12     0.267±0.22   
Dichloromethane             0.667±0.17       0.233±0.15     0.100±0.1     
Ethyl acetate            0.500±0.36 0.6±0.38         0.233±0.12 
Methanol                0.167±0.09 0.400±0.15     1.100±0.49 
Pentostam            0.400±0.20 0±0           0.100±0.06 
Amphotericin B            0.500±0.25 0±0           0.067±0.07 
PBS             0.800±0.25 0.960±0.3       1.733±0.30 
 
Figure 1.  Parasite burden in spleen of mice treated with W. ugandensis extracts. 
 
Key:  IP- Intraperitoneal injection; DCM – Dichloro methane; PBS – Phosphate Buffered Saline 
 
The number of L. major parasites (total LDU) was determined by counting the number of parasites 
divided by the number of host cells multiplied by the splenic weight in milligrams multiplied by 2 x 105. 
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For mice treated by intraperitoneal injection, the lesion sizes increased initially for the hexane, 
dichloromethane and ethyl acetate reaching a peak on day 28 post infection then reduced in size on 
day 42.  The difference in lesion sizes was significant in the different weeks (p=0.041). However, there 
was no significant difference in the lesion sizes for the mice treated with the four extracts (p=0.077) by 
intraperitoneal injection (Table 2).  The footpad swelling for mice treated using hexane, 
dichloromethane and ethyl acetate healed while the lesion sizes for mice treated with methanol 
increased steadily from 2.47mm to 3.57mm.  
To establish the extent of parasitism in the spleen, imprints from these organs were 
microscopically assessed after 12 weeks of infection. The parasitic burden was significantly higher 
(p<0.001) in the mice treated with methanol extracts and PBS compared to those treated with hexane, 
dichloromethane and ethyl acetate (Figure 1). 
The antimicrobial effects of W. ugandensis have previously been demonstrated (Kioy et al., 
1998; Rugutt et al., 2006). A study in Kenya showed its activity against soil pathogens namely 
Fusarium oxysporum, Alternaria passiflorae, and Aspergillus niger (Rugutt et al., 2006). Olila et al. 
(2001) have demonstrated that this plant has both antibacterial and antifungal activities. However, 
reports on the antiparasitic effects of this plant are limited since previous studies have indicated no 
activity against trypanosomes (Kioy et al., 1998) and Giardia lamblia (Johns et al., 1995). To the best 
of our knowledge, this is the first report on in vivo antileishmanial effects of W. ugandensis. 
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